Literature DB >> 23102767

Cutaneous multicentric Castleman's disease mimicking IgG4-related disease.

Mai Takeuchi1, Yasuharu Sato, Katsuyoshi Takata, Keita Kobayashi, Kyotaro Ohno, Noriko Iwaki, Yorihisa Orita, Tadashi Yoshino.   

Abstract

Castleman's disease, an uncommon lymphoproliferative disorder, can be difficult to differentiate from immunoglobulin (Ig) G4-related disease. The latter is typically characterized by elevated serum IgG4 levels and abundant IgG4-positive cells. However, multicentric Castleman's disease can also have elevated serum IgG4 levels and even fulfill the histological diagnostic criteria for IgG4-related disease. We present a case of cutaneous multicentric Castleman's disease mimicking IgG4-related disease. A 55-year-old Japanese woman developed erythematous and brown plaques on her back. Skin biopsy revealed regressive follicles with interfollicular plasmacytosis, and many plasma cells were positive for IgG4 (mean 263.67±79.19, range 214-355 per high power field). The IgG4-/IgG-positive cell ratios were 35.6%, 36.2%, and 48.4%, respectively, with an average of 40.6%, thus fulfilling the histological diagnostic criteria for IgG4-related disease. Furthermore, serum IgG4 level was significantly elevated (1490 mg/dl; normal range: 4.8-105 mg/dl). However, laboratory findings of anemia, hypoalbuminemia, polyclonal gammaglobulinemia, high C-reactive protein level, and elevated serum interleukin-6 level were consistent with hyper-IL-6 syndrome. Hence, the diagnosis of cutaneous multicentric Castleman's disease was made. In conclusion, IgG4-related disease cannot be differentiated from hyper-IL-6 syndromes on histology alone. Instead, laboratory analyses are necessary to distinguish between the two diseases.
Copyright © 2012 Elsevier GmbH. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23102767     DOI: 10.1016/j.prp.2012.09.006

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  7 in total

1.  Clinical characteristics of a concurrent condition of IgG4-RD and Castleman's disease.

Authors:  Xia Zhang; Panpan Zhang; Linyi Peng; Yunyun Fei; Wei Zhang; Ruie Feng; Wen Zhang
Journal:  Clin Rheumatol       Date:  2018-06-14       Impact factor: 2.980

2.  IgG4-related lung disease with atypical CT imaging: a case report.

Authors:  Jiaxuan Zhou; Xian Li; Qingsi Zeng
Journal:  J Thorac Dis       Date:  2014-12       Impact factor: 2.895

3.  Enhanced IgG4 production by follicular helper 2 T cells and the involvement of follicular helper 1 T cells in the pathogenesis of IgG4-related disease.

Authors:  Mitsuhiro Akiyama; Hidekata Yasuoka; Kunihiro Yamaoka; Katsuya Suzuki; Yuko Kaneko; Harumi Kondo; Yoshiaki Kassai; Keiko Koga; Takahiro Miyazaki; Rimpei Morita; Akihiko Yoshimura; Tsutomu Takeuchi
Journal:  Arthritis Res Ther       Date:  2016-07-13       Impact factor: 5.156

4.  Distinct features distinguishing IgG4-related disease from multicentric Castleman's disease.

Authors:  Takanori Sasaki; Mitsuhiro Akiyama; Yuko Kaneko; Takehiko Mori; Hidekata Yasuoka; Katsuya Suzuki; Kunihiro Yamaoka; Shinichiro Okamoto; Tsutomu Takeuchi
Journal:  RMD Open       Date:  2017-07-18

Review 5.  Polymyositis with elevated serum IgG4 levels and abundant IgG4+ plasma cell infiltration: A case report and literature review.

Authors:  Ryusuke Anan; Mitsuhiro Akiyama; Yuko Kaneko; Jun Kikuchi; Kazuko Suzuki; Shiro Matsubara; Tsutomu Takeuchi
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

6.  Overlap of IgG4-related Disease and Multicentric Castleman's Disease in a Patient with Skin Lesions.

Authors:  Hiroki Mochizuki; Manako Kato; Takakazu Higuchi; Ryosuke Koyamada; Satoru Arai; Sadamu Okada; Hikaru Eto
Journal:  Intern Med       Date:  2017-05-01       Impact factor: 1.271

7.  Immunoglobulin G4-related lymph node disease with an orbital mass mimicking Castleman disease: A case report.

Authors:  Feng-Yun Hao; Feng-Xia Yang; Hai-Yan Bian; Xia Zhao
Journal:  World J Clin Cases       Date:  2021-12-16       Impact factor: 1.337

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.